XtalPi, a leader in AI-driven drug discovery, and Parthenon Therapeutics, a biotech firm focused on reshaping the tumor microenvironment, have announced a collaboration to develop new therapeutic antibodies for treating solid tumors.

Under this partnership, Parthenon Therapeutics will gain access to XtalPi's XupremAb™ antibody discovery platform. This platform combines AI and wet lab techniques to generate therapeutic antibody candidates with improved efficacy and developability profiles. Together, Parthenon Therapeutics and XtalPi will employ various approaches within the XupremAb™ platform to delve deeper into the immune repertoire, consolidating a substantial dataset. XtalPi's proprietary algorithms will then be used to identify exceptional candidates.

Yi Li, VP of Antibody Discovery at XtalPi, expressed excitement about the collaboration, highlighting Parthenon Therapeutics' innovative work in tumor barrier disruption and their understanding of the target. He emphasized the potential for developing next-generation cancer therapeutics through this partnership.

Tom McCaughtry, VP – Head of Research at Parthenon Therapeutics, expressed their delight at collaborating with XtalPi. He noted the opportunity to leverage XtalPi's cutting-edge platform to uncover state-of-the-art antibody therapeutics while combining Parthenon's expertise in biotherapeutic drug discovery and insights into the tumor microenvironment.

This collaboration holds promise for the development of transformative cancer therapies.